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Abstract
Background: Characteristics of patients with community-acquired pneumonia (CAP) due to pandemic influenza A 2009
(H1N1) have been inadequately compared to CAP caused by other respiratory pathogens. The performance of prediction
rules for CAP during an epidemic with a new infectious agent are unknown.
Methods: Prospective, population-based study from November 2008–November 2009, in centers representing 70% of
hospital beds in Iceland. Patients admitted with CAP underwent evaluation and etiologic testing, including polymerase
chain reaction (PCR) for influenza. Data on influenza-like illness in the community and overall hospital admissions were
collected. Clinical and laboratory data, including pneumonia severity index (PSI) and CURB-65 of patients with CAP due to
H1N1 were compared to those caused by other agents.
Results: Of 338 consecutive and eligible patients 313 (93%) were enrolled. During the pandemic peak, influenza A 2009
(H1N1) patients constituted 38% of admissions due to CAP. These patients were younger, more dyspnoeic and more
frequently reported hemoptysis. They had significantly lower severity scores than other patients with CAP (1.23 vs. 1.61,
P= .02 for CURB-65, 2.05 vs. 2.87 for PSI, P,.001) and were more likely to require intensive care admission (41% vs. 5%,
P,.001) and receive mechanical ventilation (14% vs. 2%, P= .01). Bacterial co-infection was detected in 23% of influenza A
2009 (H1N1) patients with CAP.
Conclusions: Clinical characteristics of CAP caused by influenza A 2009 (H1N1) differ markedly from CAP caused by other
etiologic agents. Commonly used CAP prediction rules often failed to predict admissions to intensive care or need for
assisted ventilation in CAP caused by the influenza A 2009 (H1N1) virus, underscoring the importance of clinical acumen
under these circumstances.
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Introduction
Influenza pandemics are associated with significant morbidity
and mortality, mostly due to respiratory tract infections. The
severity of the three pandemics of the 20th century differed greatly,
ranging from case fatality rate of less than 0.5% for the 1968 Hong
Kong pandemic, to 3% during the Spanish flu [1]. Studies on lung
tissue from victims of the Spanish flu of 1918 have confirmed the
existence of primary viral pneumonia but also implicated bacterial
infections, most notably due to Streptococcus pneumoniae [2]. Recent
research shows that approximately one-third of patients with
community-acquired pneumonia (CAP) requiring hospitalization
have viral and bacterial co-infections, most commonly influenza
and S. pneumoniae [3]. During non-pandemic influenza seasons the
virus causes up to 8% of CAP cases warranting admission [3]. In
order to improve clinical decision making and optimize utilization
of resources in health care, clinical prediction rules and prognostic
models of patients with CAP have been developed, most notably
CURB, CURB-65, and pneumonia severity index (PSI) [4,5].
These clinical tools have been validated and their use is advocated
in clinical guidelines [6,7]. However, the prediction rules were
developed during an inter-pandemic influenza period and
therefore may not be optimally suited to predict the clinical
course in patients with CAP caused by novel infectious agents. In
2009 the World Health Organization (WHO) declared an
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influenza A (H1N1) pandemic, the first in over 40 years [8]. An
increase in the rate of severe pneumonia and a shift in the age
distribution was noted first in Mexico and subsequently in
Australia [9,10]. In contrast, data from Wisconsin suggested that
the 2009 H1N1 infections were similar in severity to seasonal
influenza [11], while a study from Singapore reported that when
compared to seasonal flu the pandemic H1N1 virus caused milder
symptoms [12]. Interestingly, however, the Wisconsin study
reported a higher proportion of H1N1 infections resulting in
pneumonia, compared with H3N2 infections [11], and Jain et al
found pneumonia in 43% of pandemic influenza admissions [13].
These apparent contradictory findings could potentially be
explained by different dominant viral subtypes in the seasonal
influenza control groups, herd immunity and host genetics [14],
but they could also be methodological, resulting in different
selection of patients. During the 2009 influenza pandemic a
prospective study on CAP was ongoing in Reykjavik, Iceland. The
pandemic offered a unique opportunity to study the impact of the
influenza A 2009 (H1N1) pandemic on hospital admissions due to
pneumonia. The primary aim of the study was to examine and
describe the symptoms, microbial etiology, treatment and
outcomes of all patients requiring hospital admission due to
CAP. The secondary aim of the study was to compare patients
admitted with CAP due to influenza A 2009 H1N1 to patients
infected by other etiologic agents. This comparison included
clinical characteristics of the patients, including symptoms, results




The study was approved by the Ethics Committee of Landspitali
University Hospital and Data Protection Authority. All partici-
pants or proxy provided written informed consent.
Setting and inclusion criteria
Iceland is a 103 000 km2 island with a 2008 mid-year
population of 319 355. Landspitali University Hospital in the
capital Reykjavik has 700 beds, constituting 70% of the national
total; serves as the only secondary care hospital for more than 63%
of the entire population and provides ICU care for over 90% of
the country. All patients $18 years of age with newly diagnosed
pneumonia requiring hospital admission from December 2008
through November 2009 were eligible for inclusion if they had a
new infiltrate on a chest-X ray confirmed by a physician and
fulfilled at least two of the following criteria: temperature ,36uC
or .38.3uC, diaphoresis, chills, chest pain, or new onset of cough
or dyspnea [15]. Admissions were reviewed daily during the study
period and all possible cases with triage diagnosis of pneumonia
were approached for participation by at least one of the authors.
Exclusion criteria were hospitalization within the preceding 14
days or significant immunosuppression (HIV infection, corticoste-
roid use exceeding 10 mg prednisolone daily, other immunosup-
pressive treatment or active cancer treatment) [15].
Data and sample collection
Following inclusion, participants underwent a structured
interview and examination. Sputum was collected for Gram-stain
and culture, blood cultures were taken prior to antibiotic
treatment and urine for pneumococcal and Legionella antigen
testing (BinaxNowH S. pneumoniae and BinaxNowH Legionella;
Inverness Medical Innovations). High-quality sputum was defined
as previously described [16]. A throat swab was collected for
polymerase chain reaction (PCR) testing. Results of other etiologic
studies, initiated by the treating physicians were noted. All
participants were assessed for Pneumonia Severity Index (PSI),
CURB-65 and APACHE II scores [4,5,17]. The Icelandic
National Registry was cross-checked to detect 30 day mortality
in discharged patients. Data on number of admissions was
provided by Landspitali University Hospital.
PCR analysis for influenza and atypical bacteria
All available samples were stored at280uC for analysis after the
study period. DNA/RNA was extracted with QIAmpH DNA
Blood Mini kit (QIAGENH) and MagNA Pure Compact Nucleic
Acid Isolation Kit I (Roche DiagnosticsH). PCR analysis for
influenza A H1N1 and atypical bacterial causes (Mycoplasma
pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila) was
performed with the 7500 Fast Real-Time PCR System (Applied
BiosystemsTM) using the AmbionH AgPath-IDTM One-Step RT-
PCR Kit (Applied BiosystemsTM) as well as the appropriate
primers (Sigma-AldrichH) and probes (Applied BiosystemsTM).
Primers and TaqMan-MGB probes for M. pneumoniae, C. pneumoniae
and L. pneumophila detection were based on the previously
established methods with minor modifications [18]. Testing for
seasonal influenza (A (H1N1), A (H3N2) and B) was performed
using the ArtusH Influenza LC RT-PCR kit (QiagenH) with the
Light Cycler 2.0 (RocheH) using established methods [19,20].
Testing was performed nonselectively on all available swabs.
Statistical analysis
Results for patients with CAP who tested positive for influenza
A 2009 (H1N1) were compared with other CAP patients. Testing
for statistical significance of numerical data was conducted using
the Mann Whitney U test while categorical data was examined
using Fisher’s exact test. In cases with more than two categories a
Pearson Chi square test was applied (SPSS Statistics 19). Results
are displayed as mean values with 95% confidence intervals (CI) or
percentages. Odds ratio was calculated and presented with the
95% CI. Results were considered statistically significant when a
two tailed P value was ,.05.
Results
Patient recruitment
During the 12 month study period a total of 397 patients were
admitted due to pneumonia. Of these, 9 were discharged without
notification to the investigators and 15 suspected CAP patients
declined participation. Of the remaining 373 patients, 60 had
exclusion criteria [15]. The remaining 313 patients constitute the
study cohort of patients with CAP requiring hospitalization,
representing 93% of eligible patients. No patients were lost to
follow-up.
Influenza epidemiology in the community
Influenza activity during the 2008–2009 influenza season was
low in Iceland. The first cases of influenza A 2009 (H1N1) in the
country were diagnosed in late May, but the activity remained low
until fall. Overall, 9887 individuals were reported with influenza-
like illness (ILI) from week 27 until week 52 in 2009. This
constitutes an incidence of 6194 cases per 100 000 inhabitants per
year [21]. The vast majority of these cases were diagnosed from
June 29th–November 6th 2009 (8650 of 9987 total cases) [21].
These findings are summarized in figure 1.
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Influenza and community-acquired pneumonia in the
hospital
Prior to the pandemic, two CAP patients were diagnosed with
seasonal H3N2 influenza pneumonia. The first patient admissions
with influenza A 2009 (H1N1) were in August and reached a peak
in October, synchronous with ILI activity in the society at large. A
total of 114 adult patients with confirmed 2009 H1N1 infection
were admitted to our centre, and 22 (19%) of those patients had
infiltrates on chest X-ray and thus were included in the study.
During its peak, influenza 2009 (H1N1) pneumonia accounted for
38% of all admissions for CAP.
Microbiology
In total, 139 of 313 patients received 154 etiologic diagnoses,
thus giving a diagnostic yield of 44.4% for the overall cohort. S.
pneumoniae was the most common pathogen, found in 30% of
diagnosed cases. During the study period no major shift in the
prevalence of pathogens other than influenza was noted (figure 2).
Bacterial co-pathogens were found in three 2009 (H1N1) CAP
patients (14%). One patient had a positive S. pneumoniae urinary
antigen test, and one had both S. pneumoniae and S. aureus cultured
from high-quality sputum. In addition Burkholderia pseudomallei was
cultured from blood of a traveler returning from Thailand. By
including patients with positive cultures from lower-quality
respiratory specimens, co-infections increase to five (23%).
Clinical characteristics of patients with influenza CAP
compared to other CAP patients
The clinical characteristics of patients with CAP due to
influenza A 2009 (H1N1) and patients with other causes for
CAP are compared in table 1. The influenza patients were
younger (P,.001) and had a lower prevalence of chronic disease
(P = .01). Further, they were more likely to report hemoptysis and
dyspnea, and had lower platelet and white blood cell counts than
patients with CAP due to other etiologies (table 2). A significant
difference in chest X-ray appearance was found, with a bilateral
interstitial infiltrate being strongly associated with the 2009
pandemic strain.
Pneumonia Severity scores
All patients received PSI, CURB-65 and APACHE II scores.
Patients with influenza A 2009 (H1N1) CAP had a significantly
lower PSI and CURB-65 scores on admission than other patients
with CAP (table 2). When the CURB-65 score was recalculated by
omitting the age criteria (one point for age over 65), the difference
between the two patient groups became non-significant (1.14 vs.
1.20). The PSI risk class is derived from various clinical parameters
which give points, including one point for each year of age for
men, and age in years210 for women [5]. The difference in mean
age between the two groups (44.0 [37.1–50.9] vs. 64.4 [62.1–66.7])
corresponded roughly to the difference in mean PSI values (56.3
[43.8–68.7] vs. 79.2 [75.2–83.2]).
Treatment, length of stay and outcomes
All admitted patients received intravenous antibiotic therapy. In
the influenza group 86% received treatment with oseltamivir
(table 3). Influenza CAP patients more commonly received
coverage for atypical bacterial agents than other patients with
CAP. Patients with influenza pneumonia displayed a non-
significant trend towards a longer hospital stay and longer
duration of antimicrobial treatment. They also received a higher
level of care, with 41% being admitted to intensive care unit (ICU)
as compared with 6% of other CAP cases (P,.001) and 14%
requiring invasive ventilation as compared with 2% of other CAP
cases (P,.001). Influenza CAP patients admitted to ICU had
worse oxygen saturation levels than other influenza patients with
the mean worst SpO2 saturation of the groups during their first
24 hours of admission being 84% vs. 94% (P = .005). The values of
C-reactive protein (CRP) differed significantly; only three of 13
non-ICU patients had a CRP of over 100 mg/L, and two of these
had documented bacterial co-infections. In contrast, seven of nine
ICU patients had CRP over 100 mg/L. No fatalities occurred in
Figure 1. Epidemiology of influenza in Iceland, December 2008-December 2009, showing the number of reported cases of
influenza-like illness (ILI) and confirmed influenza A 2009 (H1N1) (left y-axis) and weekly ILI incidence per 100 000 population
(right y-axis). In Iceland approximately 62% of all virologically confirmed cases and ILI were in Reykjavik [21]. (Ref: http://www.influensa.is/pages/
1505).
doi:10.1371/journal.pone.0046816.g001
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Figure 2. Etiologic causes of community acquired pneumonia (CAP) identified during the 12-month study, by quarters. The
proportion of total pneumonia admissions accounted for by each etiology for each quartile is shown. Influenza during the first and second quartiles
was caused by seasonal influenza H3N2 whereas all influenza cases during the third and fourth quartiles were pandemic influenza (H1N1). Less
frequently encountered pathogens listed as ‘‘other’’ included M. catarrhalis, S. aureus, C. pneumoniae, Legionella species, P. aeruginosa as well as
various streptococcal species.
doi:10.1371/journal.pone.0046816.g002
Table 1. Comparison of CAP Patients by Etiology – Characteristics and Underlying Conditions.
Characteristics






Age, mean (95% CI), y 44.0 (37.1–50.9) 64.4 (62.1–66.7) ,.001
Male, No. (%) 13 (59) 141 (49) .65 (.27–1.57) .38
Current smokers, No. (%) 8 (36) 57 (20) 2.35 (.94–5.86) .10
Alcohol abuse, No. (%) 2 (9) 18 (6) 1.52 (.33–7.00) .64
Immune suppressionb, No.(%) 0 (0) 25 (9) .91 (.88–.95) .24
Medication use at admission, No. (%)
Corticosteroids 1 (5) 28 (10) .45 (.06–3.45) .71
PPI 3 (14) 83 (29) .40 (.11–1.37) .21
Statins 3 (14) 65 (22) .55 (.16–1.91) .43
Antibiotics 10 (45) 97 (33) 2.0 (.84–4.8) .16
Underlying conditions, No. (%)
COPD 2 (9) 81 (28) .26 (.06–1.13) .08
Asthma 3 (14) 41 (14) .96 (.27–3.40) .99
DM I 0 (0) 3 (1) .99 (.98–1.00) .99
DM II 1 (5) 38 (13) .32 (.04–2.43) .33
Ischemic heart disease 1 (5) 63 (22) .17 (.023–1.31) .06
Heart failure 2 (9) 35 (12) .73 (.16–3.26) .99
Cerebrovascular disease 0 (0) 18 (6) .94 (.91–.97) .63
Renal failure 1 (5) 31 (11) .40 (.05–3.07) .71
Liver disease 1 (5) 5 (2) 2.72 (.30–24.39) .36
Malignancy 0 (0) 9 (3) .97 (.95–.99) .99
Any chronic diseasec 7 (32) 172 (59) .32 (.13–.80) .01
CAP, community acquired pneumonia; CI, confidence interval; PPI, proton pump inhibitor; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
aP values,.05 shown in bold.
bImmune suppression due to medications or malignancy.
cAny chronic disease is a composite of the conditions listed above.
doi:10.1371/journal.pone.0046816.t001
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Table 2. Comparison of CAP Patients by Etiology – Symptoms, Test Results and Severity Scores.
Characteristics
2009 (H1N1) Influenza CAP
(n=22)
CAP, other Etiology
(n =291) Odds ratio (95% CI) P valuea
Self-Reported Symptoms, No. (%)
Cough 20 (90) 229 (79) 2.71 (.62–11.90) .27
Fever 21 (95) 243 (84) 4.15 (.55–31.58) .22
Sputum production 12 (55) 150 (52) 1.13 (.47–2.96) .83
Hemoptysis 6 (27) 28 (10) 3.52 (1.28–9.73) .02
Dyspnea 21 (95) 199 (68) 9.71 (1.29–73.28) .01
Headache 12 (55) 95 (33) 2.48 (1.03–5.94) .06
Abdominal pain 4 (18) 40 (14) 1.39 (.45–4.33) .53
Chest pain 9 (41) 132 (45) .83 (.35–2.01) .83
Diaphoresis 12 (55) 83 (29) 2.37 (.98–5.72) .06
Chills 14 (64) 159 (55) 1.45 (.59–3.57) .51
Diarrhea 7 (32) 43 (15) 2.69 (1.04–6.99) .06
Vital signs on admission, mean (95% CI)
Temperature, uC 38.4 (38.0–38.7) 38.1 (38.0–38.2) .17
Heart rate, min21 102 (93–111) 97 (95–100) .38
Systolic BP, mm Hg 128 (119–136) 130 (127–133) .83
Diastolic BP, mm Hg 70 (66–74) 69 (67–70) .54
MAP, mm Hg 89 (85–94) 89 (87–91) .68
RR, min21 25 (21–29) 24 (23–25) .66
SpO2, % 93 (91–95) 92 (91.5–93) .96
SpO2 worst valueb, % 90 (86–94) 92 (91–92) .33
Blood test results, mean (95% CI)
WBC count, 103/mL 7.9 (5.4–10.4) 12.8 (12.1–13.5) ,.001
WBC count, worst value, 103/mL 7.8 (5.2–10.3) 13.2 (12.5–13.9) ,.001
Hemoglobin, g/dL 13.9 (13.1–14.6) 12.9 (12.7–13.1) .01
Hematocrit, % 39.7 (37.8–41.6) 37.9 (37.4–38.5) .03
Hematocrit, worst value, % 38.1 (36.0–40.3) 36.3 (35.7–36.9) ,.05
Platelet count,6103/mL 208 (166–250) 252 (239–265) .01
Sodium, mEq/L 137 (136–138) 139 (138–139) .004
Sodium worst value, mEq/L 137 (136–138) 139 (138–139) .01
Potassium, mEq/L 3.9 (3.7–4.1) 4.0 (3.97–4.1) .12
Potassium worst value, mEq/L 3.9 (3.7–4.1) 4.0 (3.9–4.1) .18
Urea, mg/dL 14.6 (10.9–18.5) 20.5 (18.5–22.4) .04
Glucose, mg/dL 110 (97–123) 132 (124–141) .09
CRP, mg/L 120 (83–157) 133 (121–144) .71
Radiological results, No. (%)
Lobar infiltrate 7 (32) 202 (69%) .21 (.08–.52) .001
Bilateral interstitial infiltrate 11 (50) 27 (9) 9.78 (3.88–24.65) ,.001
Other appearance 4 (18) 62 (22) .82 (.27–2.51) .99
Severity scores, mean (95% CI)
PSI score 2.05 (1.60–2.49) 2.87 (2.73–3.01) ,.001
CURB-65 score 1.23 (.96–1.50) 1.61 (1.52–1.70) .02
APACHE II score 7.41 (5.64–9.18) 9.38 (8.78–9.99) .09
CAP, community acquired pneumonia; CI, confidence interval; BP, blood pressure; MAP, mean arterial pressure; RR, respiratory rate; SpO2, pulse-oximetry; WBC, white
blood cell; CRP, C-reactive protein; PSI, pneumonia severity index.
aP-values,.05 shown in bold.
bWorst value denotes the worst noted value during the first 24 hours of admission.
doi:10.1371/journal.pone.0046816.t002
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the influenza group compared with a mortality of 3% (n = 10) in
the non-influenza group.
Discussion
Here, we present the results of a prospective population-based
study of influenza in the context of pneumonia, a serious clinical
presentation of pandemic influenza. We are not aware of any
prospective studies comparing clinical characteristics of patients
admitted with 2009 H1N1 influenza pneumonia with those of
CAP caused by other pathogens. During the height of the
pandemic in Iceland, 38% of patients admitted with CAP tested
positive for H1N1. Almost one in five (19%) admitted patients with
confirmed influenza had concurrent pneumonia. This is higher
than figures from Argentina (11%) and Beijing (12%), and similar
to Mexico City (18%), while much higher figures were reported
from California (66%) and national sampling from the United
States (43–46%) [13,22,23,24,25,26]. It is important to note the
extremely variable methodology and setting of these studies which
might explain the different results. The admission rate of 41 per
100 000 inhabitants in our study was similar to figures from the
US, where rates of 38 per 100 000 inhabitants were noted during
the peak of the pandemic [27].
Interestingly, hospital admissions for CAP caused by agents
other than influenza were similar to or below the study period’s
monthly average for three of the four months of peak ILI activity
(data not shown). Therefore, the epidemic in the community did
not seem to lead to any discernible increase in bacterial
pneumonia requiring admission (See figure S1). It is important
to note that preventive measures, such as mass vaccination,
initiated in mid-October, and antiviral treatment were being
enforced simultaneously. Two weeks after conclusion of our study
24% of the population had been vaccinated according to official
figures.
The timing of the study provided a unique opportunity to
compare patients with CAP due to pandemic influenza A 2009
(H1N1) to those with CAP caused by other agents. Our results
demonstrate that pneumonia caused by the novel pandemic strain
was more severe than CAP of other microbial etiology, despite the
fact that these were younger patients with less co-morbidity than
other CAP patients. Patients with CAP due to influenza A 2009
(H1N1) were significantly more likely to require ICU admission
and receive invasive ventilation. Previous studies from tertiary care
hospitals have indicated a more severe course of illness and a
higher mortality rate [28], which might be explained by selection
bias. However, our prospective population-based study is in
agreement with those results.
As a group, patients with CAP due to pandemic influenza A
2009 (H1N1) were more symptomatic than other CAP patients.
Interestingly one-third of influenza pneumonia patients reported
hemoptysis, which corresponds to the descriptions of the initial
patients in Mexico, but is rarely encountered in CAP from other
etiologies [24,29]. A bilateral interstitial infiltrate on a chest X-ray
was characteristic but one third of the influenza patients had a
lobar infiltrate, similar to previous descriptions [30].
The prevalence and importance of bacterial co-infections with
S. pneumoniae and S. aureus in patients with influenza is debated [2].
Our results demonstrate unequivocal co-infections in only three
patients (14%). Historical reports and some more recent studies
have indicated a much higher rate [31,32]. Antibiotics prior to
admission might give a partial explanation; 11 of 22 patients
reported having received antibiotics and none of the co-infected
patients was in this group. Even when lower-quality specimens
were included the rate of co-infection was 23%. However, if
patients with previous antibiotic exposure are excluded, and those
with positive lower-quality respiratory specimens are included, the
proportion of bacterial co-infections reaches 45%. Some studies
have shown higher levels of suspected co-infection, but they often
Table 3. Comparison of CAP Patients by Etiology – Treatment and Outcome.
2009 (H1N1) Influenza CAP (n=22) CAP, other Etiology (n =291) Odds ratio (95% CI) P valuea
Therapy, No. (%)
IV abx therapy 22 (100) 291 (100)
oseltamivir 19 (86)
Atypical coverageb 15 (68) 111 (38) 3.53 (1.39–8.92) .01
Duration of abx, mean (CI), days 14.3 (8.5–20.2) 11.5 (11.0–11.9) .75
Length of stay, mean (CI),days 9.6 (6.2–13.0) 7.4 (6.8–7.9) .13
ICU admission 9 (41) 16 (5) 11.7 (4.4–31.5) ,.001
Invasive ventilation 3 (14) 5 (2) 9.03 (2.01–40.67) .01
In-hospital mortality 0 (0) 10 (3) .96 (.94–.99)
Etiologic testing, No (%)
Sputum acquired 10 (45) 147 (51) .83 (.35–1.98) .83
Representive sputum acquired 5 (23) 97 (33) .60 (.21–1.67) .48
Blood culture 22 (100) 211 (73) .73 (.68–.78) .002
BAL 1 (5) 8 (3) 1.69 (.20–14.11) .49
UAT S. pneumoniae 15 (68) 210 (72) .83 (.33–2.10) .81
UAT L. pneumophila 13 (59) 197 (68) .69 (.29–1.67) .48
CAP, community acquired pneumonia; CI, confidence interval; IV, intravenous; abx, antibiotic; UAT, urine antigen test;; ICU, intensive care unit; BAL, bronchoalveolar
lavage.
aP-values,.05 shown in bold.
bAtypical coverage denotes empiric antimicrobial treatment including coverage for ‘‘atypical’’ bacterial organisms.
doi:10.1371/journal.pone.0046816.t003
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rely on upper airway samples which are not adequate to diagnose
a lower respiratory tract infection with pathogens such as S.
pneumoniae [33].
PSI and CURB-65 are two major scoring systems with similar
validity, designed to risk-stratify patients presenting with CAP.
Both scoring systems are recommended for routine use by most
major published pneumonia management guidelines, including
the Infectious Diseases Society of America, American Thoracic
Society and the British Thoracic Society [6,7]. Although originally
designed to designate patients suitable for out-patient treatment,
these scoring systems have also been used to help stratify inpatients
according to severity with such recommendations entering some
national guidelines [34]. Despite having a more severe disease the
2009 (H1N1) CAP patients had, paradoxically, lower PSI and
CURB-65 scores than other CAP patients. In addition, neither
score predicted the need for ICU admissions or mechanical
ventilation among the influenza patients. This discrepancy seems
to be explained by points given for age. This has been previously
noted for CURB-65, but the results were based on retrospective
analysis of selected cases from a referral centre and thus prone to
selection and referral biases [35]. The failures of both scoring
systems points out weaknesses in the current methods to stratify
patients with CAP. Although increasing age is traditionally
associated with greater severity and worse prognosis for most
illnesses and thus independently increases severity scores such as
PSI, APACHE II and SAPS II, this pandemic proves to be an
exception. It is plausible that given the higher prevalence of cross-
reactive antibodies in the population above the age of 60,
increasing age was relatively protective against severe illness
[36]. Importantly, the PSI and CURB-65 scoring systems were
developed decades after the last influenza pandemic and not
intended for use during an epidemic with a novel viral agent [5].
Our results underscore the importance of clinical judgment in
decision-making, as the average PSI and CURB-65 scores for
admitted patients were below criteria recommending admission to
hospital [4,5]. Therefore, we feel that neither of these scores in
their present form should be used for clinical decision-making
during epidemics in populations with low herd immunity. New or
amended scoring systems with less focus on age might prove to be
more robust under these conditions.
While most demographic data in our study corresponds to
previously published results we had no mortality in our group.
There were two deaths in the country attributed to the pandemic,
neither of which fulfilled the study criteria for CAP [21]. Even by
including these patients the mortality for inpatients (1.5%) was
substantially lower than reported from Beijing (14%), Mexico City
(39%) and the United States (4.6%) [24,25,27]. The difference
may be related to sample size, inclusion criteria, differences in
patient host factors, pneumococcal carriage in the population, or
the level of care in these studies [37].
The major strength of this study is the prospective population-
based design, with high inclusion rate of consecutive patients, thus
providing high external validity. All available samples were
screened for influenza which provides detailed information
regarding the impact of the epidemic. However, it has limitations.
Despite including 94% of available patients the number of cases is
low. It is possible that the proportion of CAP attributable to
influenza may be underrated due to false negative test results from
PCR of nasopharyngeal swabs. However, no increase in undiag-
nosed or bacterial pneumonia was noted during the epidemic
period suggesting that this should was not a major problem.
Broncho-alveolar lavage may be more sensitive in the diagnosis of
influenza pneumonia [35], but subjecting all admitted patients
with CAP to bronchoscopy is not ethically acceptable. Further-
more, occasional patients may have been admitted to smaller
hospitals. This is unlikely to make an impact in our results
however, since our hospitals hold 70% of all hospital beds in the
country.
In summary, patients with pneumonia due to influenza A 2009
(H1N1) were younger than other patients with CAP, and required
intensive care and mechanical ventilation more frequently. Despite
having a more severe disease, they had lower PSI and CURB-65
scores on admission, suggesting that modification of these
prediction rules may be warranted in the setting of novel
pathogens to which the herd immunity is low. Last, but not least
these results remind us of the importance of clinical acumen in
decision making.
Supporting Information
Figure S1 Total number of patients admitted with community-
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